Please use this identifier to cite or link to this item:
|Title:||Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine|
|Keywords:||Pneumococcal conjugate vaccine|
|Citation:||Russell, F.M., Balloch, A., Tang, M.L.K., Carapetis, J.R., Licciardi, P., Nelson, J., Jenney, A.W.J., Tikoduadua, L., Waqatakirewa, L., Pryor, J., Byrnes, G.B., Cheung, Y.B., Mulholland, E.K. (2009-09-18). Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine. Vaccine 27 (41) : 5685-5691. ScholarBank@NUS Repository. https://doi.org/10.1016/j.vaccine.2009.06.098|
|Abstract:||The aim was to identify an appropriate infant pneumococcal vaccination strategy for resource poor countries. Fijian infants received zero, one, two, or three doses of 7-valent pneumococcal conjugate vaccine (PCV) in early infancy. Following three PCV doses, geometric mean concentration (GMC) to all seven serotypes were ≥1.0 μg/mL, and >85% of children achieved antibody levels ≥0.35 μg/mL at 18 weeks. Following two doses, GMC were lower for 6B, 14, and 23F, but higher for 19F compared with three doses. Following a single dose, significant responses were seen for all serotypes post-primary series compared with the unvaccinated. By 12 months, differences between two and three doses persisted for serotype 14 only. Although GMC following three doses are higher than after two doses, the differences were small. A single dose may offer some protection for most serotypes. © 2009 Elsevier Ltd. All rights reserved.|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Sep 21, 2018
WEB OF SCIENCETM
checked on Sep 11, 2018
checked on May 25, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.